Chronic psychological stress accelerates oral squamous cell carcinoma by activating the hypothalamic–pituitary–bone marrow axis and reshaping the tumor microenvironment, according to research at the West China Hospital of Stomatology, Sichuan University.
Modern life exposes people to persistent social, environmental, and occupational stressors that disrupt immune homeostasis. The study, published in the International Journal of Oral Science, identifies a central nervous system-driven circuit in which chronic stress triggers the HPB axis.
This neuroendocrine shift raises pituitary production of proopiomelanocortin and circulating alpha-melanocyte-stimulating hormone. The process expands polymorphonuclear myeloid-derived suppressor cells in the bone marrow, suppresses CD8+ T cells, and promotes tumor growth.
Combining a melanocortin 1 receptor inhibitor with anti-PD-1 checkpoint therapy produced the smallest tumors and greatest CD8+ T cell infiltration in experimental models. The authors said that this work reframes chronic stress as an active biological driver rather than a purely psychological burden.
Stress activates the sympathetic nervous system to promote tumor progression
Prolonged activation of both the sympathetic nervous system and the hypothalamic-pituitary-adrenal axis has been linked to chronic stress in a systematic review. This response increases the release of catecholamines and glucocorticoids.
These mediators influence immune function and the tumor microenvironment by decreasing antitumor immune surveillance, raising inflammation, and activating proliferation pathways. However, the available evidence remains largely associative and does not establish a direct causal relationship.
Researchers distinguished cancer types by survival rates and identified specific site mechanisms. In breast cancer, activation of beta-adrenergic pathways promotes tumor growth, angiogenesis, and metastasis. Prostate cancer shows activation of antiapoptotic mechanisms.
Pancreatic cancer involves inflammatory mechanisms, particularly those involving interleukin-6. Ovarian cancer shows increased levels of inflammatory and proangiogenic mediators, including interleukin-6 and vascular endothelial growth factor.
Modulating neuroimmune pathways offers potential therapeutic interventions
Another review examined approaches under investigation to modulate neuroimmune pathways activated by chronic stress.
Alprazolam restricted tumor progression within an experimental breast cancer model through actions on a neuroimmune network involving tumor-associated macrophages, myeloid-derived suppressor cells, and glucocorticoids. Beta-blockers such as propranolol block beta-adrenergic signaling pathways that contribute to an immunosuppressive environment.
In gastric cancer models, propranolol reduced tumor microvascular density and limited metastatic spread. Longer progression-free survival was observed when propranolol was added to chemotherapy for patients with advanced breast cancer in a pilot trial.
Tumor advancement in glioma models is driven by chronic stress via decreased secretion of monocyte inflammatory protein-1 alpha, also referred to as CCL3. Conversely, CCL3 administration has been shown to restore antitumor immunity and enhance the efficacy of anti-PD-1 agents.
Psychological Support in Clinical Cancer Care
Physiologic resilience in patients may be indirectly boosted, and treatment outcomes potentially enhanced, through nonpharmacologic psychological interventions designed to lower stress-induced biological reactions.
Several approaches have proven effective in reducing psychological distress. Anxiety and depression can be lessened while quality of life is enhanced through mindfulness-based interventions, stress management programs, and cognitive-behavioral therapies. Studies have reported reductions in cortisol levels and inflammatory markers. Some findings suggest a potential effect on survival, although further research is needed to confirm this association.
Although the relationship between chronic stress and cancer progression is not yet understood, the authors said psychological care should be integrated into the cancer care pathway. Enhancing patients’ quality of life by mitigating psychological distress appears to be a key objective that may additionally support better clinical outcomes.
Common Questions on Stress and Cancer
How does chronic stress affect the immune system in cancer?
Chronic stress activates the sympathetic nervous system and hypothalamic axes, releasing catecholamines and glucocorticoids that suppress CD8+ T cells and expand suppressor cells in the bone marrow.
What specific cancer types are linked to stress pathways?
Research has examined mechanisms in breast, prostate, pancreatic, and ovarian cancer, as well as in glioma and oral squamous cell carcinoma models.
Are beta-blockers used in cancer treatment?
Drugs such as propranolol are under investigation to block signaling pathways that contribute to an immunosuppressive environment and tumor progression.
Is there a direct causal link between stress and tumor growth?
The link between psychological stress and tumor progression lacks a demonstrated direct causal relationship based on the current evidence, which remains largely associative.